BIND, Rusnano portfolio company, completes IPO at NASDAQ
BIND Therapeutics, a biotech portfolio company of Rusnano, Russia?s nanotech giant, has completed an IPO at NASDAQ at $15 a share
Rusnano, Russia?s nanotech giant, announced last week that BIND Therapeutics, Inc., its biotech portfolio company, has completed an initial public offering (IPO) at NASDAQ. The company is reported to have floated 4,700,000 common shares at $15 per share. As a result, BIND Therapeutics has raised $70.5m. The company shares are now listed as ?BIND? at NASDAQ Global Select Market and were first traded at the U.S. exchange on September 20. BIND Therapeutics is Rusnano?s first portfolio company to have successfully completed an IPO in the American market...
Rusnano, Russia?s nanotech giant, announced last week that BIND Therapeutics, Inc., its biotech portfolio company, has completed an initial public offering (IPO) at NASDAQ. The company is reported to have floated 4,700,000 common shares at $15 per share. As a result, BIND Therapeutics has raised $70.5m. The company shares are now listed as ?BIND? at NASDAQ Global Select Market and were first traded at the U.S. exchange on September 20. BIND Therapeutics is Rusnano?s first portfolio company to have successfully completed an IPO in the American market...
Похожее
The portfolio Company of ROSNANO “BIND Therapeutics” has conducted IPO at NAS
Портфельная компания РОСНАНО BIND Therapeutics провела IPO на NASDAQ
Rusnano asset and Pfizer to develop and market new drugs
Two portfolio companies of ROSNANO are named Technology Pioneers 2014
Rusnano approves more funding for its Siberian lithium-ion battery maker